ImmunoCellular Therapeutics Ltd (NYSE American:IMUC)

0.265
Delayed Data
As of 3:58pm ET
 +0.0002 / +0.08%
Today’s Change
0.17
Today|||52-Week Range
2.79
-16.14%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$7.7M

Company Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.

Contact Information

ImmunoCellular Therapeutics Ltd.
30721 Russell Ranch Road
Westlake Village California 91362
P:(818) 264-2300
Investor Relations:

Employees

Shareholders

Other institutional2.00%
Mutual fund holders0.22%
Individual stakeholders0.02%

Top Executives

Gary S. TitusChairman & Secretary
Anthony J. GringeriPresident, Chief Executive Officer & Director
David E. FractorChief Financial & Accounting Officer
Steven J. SwansonSenior Vice President-Research